From: Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
Factor
p =
OR*
95% CI
Age < 35 years
0.097
0.53
1.04-3.5
Number of metastatic sites (1 versus 2)
0.037
1.91
0.25-1.12